Scribe Therapeutics Inc(SCTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:47 PM ET (Korea 9/26 08:47)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 36.14% | Shs Outstand | 18.9M | Perf Week | -35.52% |
| Market Cap | 0.40B | Forward P/E | - | EPS next Y | - | Insider Trans | 224% | Shs Float | 12.1M | Perf Month | -32.87% |
| Enterprise Value | 0.52B | PEG | - | EPS next Q | -0.85 | Inst Own | 25.84% | Short Float | 6.54% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 15.19% | Short Ratio | 2.51 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.79M | Perf YTD | -14.88% |
| Book/sh | -8.71 | P/C | 9.37 | EPS past 3/5Y | - | ROE | - | 52W High | -46.26% ($39.60) | Perf Year | - |
| Cash/sh | 2.27 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 22.97% ($17.31) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 19.49% 13.76% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.93 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.57 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 36.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.57 | Sales Q/Q | - | SMA20 | -26.52% ($28.96) | Beta | - | Target Price | $57 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/2 | SMA50 | -20.33% ($26.71) | Rel Volume | 1.46 | Prev Close | $21.61 |
| Employees | 98 | LT Debt/Eq | - | EPS/Sales Surpr. | 27.58% -38.16% | SMA200 | -20.33% ($26.71) | Avg Volume(3M) | 0.31M | Price | $21.28 |
| IPO | 2026/7/24 | Option/Short | No/Yes | Trades | 4498 | Volume | 458,849 | Change | -1.53% |
🧬 This is a clinical-stage biotech company developing therapeutics that work directly inside the body based on gene-editing technology. Headquartered in California, USA, it is developing long-acting gene therapy candidates targeting cardiovascular and metabolic diseases, and funds its research through collaboration agreements with major pharmaceutical companies.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded more than usual That is 146% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ARKG <0.01% It ranks #246 of 593 in the industry
Based on market cap of $403M.
RLMD#243 $409M PER - 
YDES#244 $406M PER - 
SPRY#245 $406M PER - SCTX#246 $403M PER - 
EDIT#247 $396M PER - 
FAQ
What kind of company is SCTX?
SCTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SCTX?
The market cap of SCTX is approximately $403M, ranking 3,388 within its sector.
What is the 52-week high and low for SCTX?
SCTX has recorded a 52-week high of $39.60 and a low of $17.31.
